DIA Home
Learning Center Home
Content Schedule
My Account
Search
Contact Us
Log-in / Create Account
DIA 48th Annual Meeting
Click here
to go to the previous page
Risk Evaluation and Mitigation Strategy (REMS): 18-Month Assessment Report of Dalfampridine Extended Release 10 mg Tablets
Track :
Professional Poster Session 1, Tuesday June 26, 2012
Program Code: T01
PRESENTER :
Calvin Mai,
Acorda Therapeutics, Inc., United States
Handout Online
(Code: T01)
Attendee
:
Attendees Login